Michael Liu
Contributor since: 2014
Latest Articles
MamaMancini's: 40% Organic Growth Selling...Meatballs
The Long Case For Hexcel
Biomerica: The Next Major IBS Product
Leatt: Nonsensical Sell-Off Opens Immense Opportunity
QHR Corp: A Rapidly Growing Market Leader
Constellation Software: A Highly Sustainable Compounder
Where Food Comes From: A Venture Capitalist's Dream
AG&E Holdings: Heads I Win, Tails I Don't Lose
Monsanto: An Analysis Using Philip Fisher's Criteria
Leatt: A Microcap Market Leader With Significant Growth Potential
Boeing: Huge Long-Term Growth Potential Based On Philip Fisher's Criteria
Visa: A Potential Long-Term Growth Investment Based On Philip Fisher's Criteria
Adobe: Huge Long-Term Growth Potential Based On Philip Fisher's Criteria
Inventure Foods: Material Short And Long-Term Upside To This High-Growth Food Provider
Molson Coors: Sustainability, Competitive Advantages, And Growth Potential For A Cheap Price
United Natural Foods: Massive Long-Term Upside Potential For A Slight Premium Valuation
Morphosys: Dozens Of Partnerships And Self-Funded Growth
General Motors: Huge Upside Potential Based On Radical Undervaluation And Institutional Accumulation
ALJ Regional Holdings: A Nice Acquisition, But Don't Expect Any More
Alliance Data Systems: Strong And Sustainable Growth At A Premium Valuation
Pinnacle Foods: High Quality Company Trading At A High Price
Paratek: One Step Closer To Omadacycline's Blockbuster Potential Commercialization
Innovative Food Holdings Trades At A Fraction Of Peers' Valuations With A Superior Business Model And Strong Growth Trends
American Airlines Investors Are Ignoring Major Risks To The Company
Celgene: Philip Fisher's Kind Of Company
Airlines: The Coming Days Will Test The Power Of The Oligopoly
PD-Rx: A Nano-Cap Serving A Niche Industry
Aratana: A Potential Long-Term Leader In The Huge Pet Therapeutics Market
Bioqual: Q3 Results Outline Lack Of Visibility Risk In The Company
Mer Telemanagement: Vexigo Acquisition Brings A Return To Profitability And Upside Potential
Paratek Pharmaceuticals: The Next Blockbuster Antibiotic At A Third Of The Valuation
Adamis: An Easy Double After The FDA's CRL, With Even More Long-Term Growth Potential